2019
Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes
Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE. Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes. Gynecologic And Obstetric Investigation 2019, 84: 290-297. PMID: 30602164, DOI: 10.1159/000493132.Peer-Reviewed Original ResearchConceptsType 2 cancerHormone replacement therapyCox regression modelType 2 diseaseRisk factorsEndometrial cancerType 1Use of HRTLess obese patientsBaseline risk factorsEndometrial cancer casesMajor cardiovascular diseasesObese patientsOral contraceptivesOverall survivalClinical courseDiabetes mellitusRetrospective reviewRegression modelsReplacement therapyCardiovascular diseaseCancer casesAdvanced stageHigh mortalityRecurrence
2006
MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer.
Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. The Yale Journal Of Biology And Medicine 2006, 79: 153-63. PMID: 17940625, PMCID: PMC1994803.Peer-Reviewed Original ResearchConceptsOvarian cancer cellsEpithelial ovarian cancerExpression of MyD88Ovarian cancerOverall survivalCancer cellsMyD88 expressionRecurrent epithelial ovarian cancerShorter progression-free intervalOvarian malignant tumorsPositive ovarian cancer cellsProgression-free intervalTime of surgeryPaclitaxel combination chemotherapySpecific tumor markersPure cancer cellsCytotoxic agent paclitaxelPaclitaxel chemoresistanceWestern blot analysisPaclitaxel chemotherapyClinical courseCombination chemotherapyAppropriate therapyProinflammatory cytokinesPoor response